Contact Us | Refer a Colleague
 
   
ACE Inhibitors for Reducing Global CV Risk
Evidence Against a Class Effect
About the Clinical Letter
This clinical bulletin, developed by Domenic Sica, MD, briefly reviews data from clinical trials that evaluated treatment options for patients with both hypertension and other risk factors for cardiovascular disease. It also highlights the ability of angiotensin-converting enzyme inhibitors to improve patients' overall cardiovascular risk profile while lowering blood pressure levels.
 
NOT FOR CREDIT Download
 
All Rights Reserved. Use of this Web Site is governed by the Terms of Use | Privacy Policy
The Cardiovascular & Metabolic Health Foundation, Inc. ("CMH") is a non-profit corporation of the State of New Jersey.
© 2007 Cardiovascular and Metabolic Health Foundation. All rights reserved.